Press releases

The voluntary recall does not affect patients who have already received a TAXUS stent.

Company plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.

Company announces launch of a public offering of $500 million aggregate principal amount of senior notes.

A live webcast and replay of the June 9th conference session will be available.

Company estimates that its share of the U.S. drug-eluting stent market - as of May 31st - continues to be in excess of 70 percent, on a reorder basis.

Acquisition will bring neuromodulation technology, including a range of neurostimulators, programmable drug pumps and cochlear implants.

(May 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a decision by the U.S. District Court in Wilmington,...

Trial assessed the safety and efficacy of a moderate-release formulation paclitaxel-eluting stent in high-risk patients, including long lesions with overlapping stents, small vessels and diabetics.

Company made the announcement at the annual Paris Course on Revascularization, the largest interventional cardiology conference in Europe.

Company expects to announce 30-day results at the 2004 Transcatheter Cardiovascular Therapeutics conference in September.